Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.68 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | CHKA | P35790 | 1/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.45 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.45 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.45 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.45 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL659692 | 0.98 | POLB (0.65) | POLBCA2CA12CA1CA9 | |
| SCHEMBL2915853 | 0.92 | POLB (0.58) | POLBCA2CA12CA1CA9 | |
| Trifluoroacetic Acid SCHEMBL29701104 | 0.87 | POLB (0.52) | POLBCA2CA12CA1CA9 | |
| SCHEMBL25253878 | 0.87 | POLB (0.52) | POLBCA2CA12CA1CA9 | |
| Acrylamide SCHEMBL28297013 | 0.85 | POLB (0.50) | POLBCA2CA12CA1CA9 | |
| SCHEMBL13176215 | 0.82 | POLB (1.00) | POLBEPHX2KMT2ACYP1A2 | |
| Tert-Butyl Formate SCHEMBL28827129 | 0.81 | POLB (0.46) | POLBCA2CA12CA1CA9 | |
| Trifluoroacetic Acid SCHEMBL29701099 | 0.81 | POLB (0.46) | POLBCA2CA12CA1CA9 | |
| SCHEMBL4437911 | 0.80 | POLB (0.54) | POLBEPHX2CHRNB2CHRNA3CHRNA4 | |
| SCHEMBL22359169 | 0.80 | CYP1A2 (0.68) | POLBCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 365 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119698278-A | Small molecule modulators of alveolar type 2 cell proliferation for the treatment of pulmonary diseases | 斯克里普斯研究学院 | 2025-03-25 | — | — | CN | claimed |
| US-20230212131-A1 | COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF | ANIMA BIOTECH INC. (US) | 2023-07-06 | — | — | US | claimed |
| EP-4161921-A1 | COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF | Anima Biotech Inc. (US) | 2023-04-12 | — | — | EP | claimed |
| CN-115916776-A | Collagen 1 translation inhibitors and methods of use thereof | 艾尼莫生物科技公司 | 2023-04-04 | — | — | CN | claimed |
| EP-4028005-A1 | CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS | Prelude Therapeutics, Incorporated (US) | 2022-07-20 | — | — | EP | claimed |
| CN-114728009-A | Preventing or treating diseases and disorders associated with tissue damage | 李晓祥 | 2022-07-08 | — | — | CN | claimed |
| WO-2021050824-A1 | CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS INCORPORATED (US) | 2021-03-18 | — | — | WO | claimed |
| CN-104870442-B | bicyclic heterocyclic compounds and their therapeutic use | 阿斯特克斯治疗有限公司 | 2018-10-19 | — | — | CN | claimed |
| CN-104427873-A | Certain chemical entities, compositions, and methods | NEUPHARMA INC | 2015-03-18 | — | — | CN | claimed |
| EP-1317454-B1 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMA (US) | 2011-05-25 | — | — | EP | claimed |
| EP-1959960-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | Cytokinetics, Inc. (US) | 2008-08-27 | — | — | EP | claimed |
| WO-2007070683-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. (US) | 2007-06-21 | — | — | WO | claimed |
| US-20040023979-A1 | Process for making substituted thiazolyl-amino pyridines | ZHAO MATTHEW M (US) | 2004-02-05 | — | — | US | claimed |
| US-6683077-B2 | 4H-3,1-BENZOXAZIN-4-ONE COMPOUNDS OF GIVEN FORMULA; HERPES INFECTIONS; ASSEMBLIN PROTEASE INHIBITORS | G.D. SEARLE & CO. | 2004-01-27 | — | — | US | claimed |
| EP-1301484-A2 | CAPSAICIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2003-04-16 | — | — | EP | claimed |
| US-20030022895-A1 | 2-Amino-benzoxazinones for the treatment of viral infections | G.D. SEARLE & CO. | 2003-01-30 | — | — | US | claimed |
| US-6380189-B1 | FOR TREATING HERPES-RELATED DISORDERS | G.D. SEARLE & CO. | 2002-04-30 | — | — | US | claimed |
| WO-2002008221-A2 | CAPSAICIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2002-01-31 | — | — | WO | claimed |
| EP-1024407-A1 | POSITIVE PHOTOSENSITIVE POLYIMIDE COMPOSITION | PI R & D Co Ltd (JP) | 2000-08-02 | — | — | EP | claimed |
| WO-1995029892-A1 | HYDROXAMIC ACID AND AMINO ACID DERIVATIVES AND THEIR USE AS ANTI-ARTHRITIC AGENTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-11-09 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030022895-A1 | 2-Amino-benzoxazinones for the treatment of viral infections | IFNAR1, IL4I1, HAX1 | POLB 2432/4885CA2 1655/4885CA12 3354/4885 |
| US-20040023979-A1 | Process for making substituted thiazolyl-amino pyridines | ERBB2, ERBB4, TYRO3 | POLB 4443/4885CA2 2888/4885CA12 4718/4885 |
| US-20230212131-A1 | COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF | COL1A1, COL2A1, COL14A1 | POLB 554/4885CA2 4469/4885CA12 4793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.